New therapies for sepsis

CPD Anaesthesia

Volumn 4, Issue 3, 2002, Pages 130-135

  Hughes, Martin ^a   Wallace, P G M ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

ARDS; Drotrecogin alfa; Insulin; Sepsis; Steroids

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT PROTEIN; ANTITHROMBIN; ANTITHROMBIN III; BRADYKININ; CORTICOTROPIN; CYTOKINE; DROTRECOGIN; FLUDROCORTISONE; GLUCOCORTICOID; GLUCOSE; HYDROCORTISONE; INSULIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; NITRIC OXIDE; OXYGEN RADICAL; PROTEINASE; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; STEROID; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; VASOPRESSIN;

ANTIINFLAMMATORY ACTIVITY; BLEEDING; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COST OF ILLNESS; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; DRUG THERAPY; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN TREATMENT; INTENSIVE CARE UNIT; KIDNEY FAILURE; LOW DRUG DOSE; OXYGEN SATURATION; PATHOPHYSIOLOGY; REVIEW; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; THROMBOSIS; UNITED KINGDOM; UNITED STATES;

EID: 0036451051     PISSN: 14662922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Center for Disease Control: Increase in national hospital discharge survey rates for septicaemia: United States 1979-1987; MMWR Morb Mortal Wkly Rep 1990; 31-34.
2. Bone RC, Grodzin CJ, Balk BA; Sepsis: A new hypothesis for pathogenesis of the disease process. Chest 1997; 112: 235-43.
3. Intensive Care National Audit & Research Centre Case Mix Programme Database, 2001.
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al; Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome and associated costs of care. Crit Care Med 2001; 29: 1303-10.
5. Vincent JL; Dear Sirs, I'm sorry to say I don't like you. Crit Care Med 1997; 25: 372-374.
6. Spencer RC; Epidemiology of infection in ICUs. Intensive Care Med 1994; 20: S2-6.
7. Bernard GR, Vincent JL, Laterre PF, et al; Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 2001; 344 (10): 699-709.
8. Rivers E, Nguyen B, Havstad S, et al; Early goal-directed therapy in the treatment of severe sepsis and septic shock. New Engl J Med 2001; 345(19): 1368-1377.
9. Cronin L, Cook DJ, Carlet J, et al; Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430-1439.
10. Bollaert PE, Charpentier C, Levy B, et al; Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645-650.
11. Briegel J, Forst H, Haller M, et al; Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27: 723-732.
12. Annane D, Sebille V, Charpentier C, et al; Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-871.
13. Van Den Berghe G, Wouters P, Weekers Frank, et al; Intensive insulin therapy in critically ill patients. New Engl J Med 2001; 345: 1359-1367.
14. Ronco C, Bellomo R, Homel P, et al; Effect of different doses of continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet 2000; 356: 26-30.
15. Schiffl H, Lang SM, Fischer R. Daily dialysis and the outcome of acute renal failure. New Engl J Med 2002; 346: 305-310.
16. Cole L, Bellomo R, Hart G, et al; A phase II randomised controlled trial of continuous haemofiltration in sepsis. Crit Care Med 2002; 30: 100-106.